RealDolmen : Results for the Year Ended 31 March 2009
Posted on: Friday, 29 May 2009, 06:30 CDT
HUIZINGEN,
"We are pleased and proud with the results of this first year as RealDolmen. After a very strong start with solid growth across all metrics in the first half we performed relatively well in a declining market in the second half. As expected, our strong market position, good spread of customers across a number of sectors and strengthened product offering have enabled us to generate a small level of growth in revenue and maintain REBIT margins for the full year, despite a significant downturn in the market in H2.
"We expect the trading levels of Q4 to continue into the next two quarters of the current financial year, resulting in a reduction in revenues year on year although we feel confident that we can keep the impact on our margins limited as we continue to manage our cost base tightly. With the integration almost completed, and a strong balance sheet with good cash flows, we now have a RealDolmen framework in place to support organic growth and selective acquisitions, allowing us to strengthen our solutions portfolio and/or to broaden our regional coverage over the next 12 months."
http://www.realdolmen.com/newslist.aspx
SOURCE RealDolmen
Source: PR Newswire
Related Articles
- Mustang Reports Positive Results From Prefeasibility Study at Maskwa Open Pit Nickel Project
- Fronteer Development Group Inc.: Drill Results Reinforce Strong Growth Potential of Northumberland Gold Deposit in Nevada
- Cephalon Announces Positive Results From a Pivotal Study of FENTORA in Opioid-Tolerant Patients With Non-Cancer Breakthrough Pain
- DURECT Reports Positive Results From POSIDUR(TM) Phase IIb Hernia Trial, Triggering $8 Million Milestone Payment From Nycomed
- Calavo Growers, Inc. Announces Strong Growth in Fiscal 2006 Fourth Quarter and Full-Year Results
- Cephalon Announces Positive Results From Two Phase 3 Clinical Trials of FENTORA(TM) in Breakthrough Pain
- HandHeld Entertainment Sees Cash Flow Positive Results in 2007, Makes First Acquisition
- Acorda Therapeutics Announces Positive Results of Phase 3 Study of Fampridine-SR on Walking in People With Multiple Sclerosis
- Genzyme Announces Positive Results From DCOR Trial Favoring Use of Renagel
- Onfiber Continued Strong Growth in 2004
 |
 |
User Comments (0)
RSS Feeds